|Mr. Ron Squarer BSc (Biochemistry), MBA||Chief Exec. Officer and Director||1.06M||N/A||50|
|Mr. Andrew R. Robbins||Chief Operating Officer||684.38k||N/A||41|
|Mr. John R. Moore||VP, Gen. Counsel and Sec.||576.4k||N/A||53|
|Dr. Victor Sandor M.D., C.M||Chief Medical Officer||745.35k||N/A||51|
|Mr. Jason Haddock||Chief Financial Officer||N/A||N/A||47|
Array BioPharma Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule drugs to treat patients with cancer in North America, Europe, and the Asia Pacific. The companys drugs in Phase III clinical trials include Binimetinib, Encorafenib, and Selumetinib for the treatment of cancer, as well as ASC08/Danoprevir, a protease inhibitor for hepatitis C virus. Its drug candidates in Phase II clinical trials comprise Filanesib, a kinesin spindle protein inhibitor for multiple myeloma; ARRY-797, a p38 inhibitor for Lamin A/C-related dilated cardiomyopathy; ASLAN001/Varlitinib, a pan-HER2 inhibitor for gastric or breast cancer; Ipatasertib/GDC-0068, an AKT inhibitor for cancer; Motolimod/VTX-2337, a toll-like receptor for cancer; Prexasertib/LY2606368, a chk-1 inhibitor for cancer; LOXO-101, a PanTrk inhibitor for cancer; and ONT-380/ARRY-380, an HER2 inhibitor for breast cancer. The companys Phase I drugs include GDC-0994, an ERK inhibitor for cancer; and ARRY-382, a CSF1R inhibitor for cancer, as well as Phase Ib drug candidate comprises GDC-0575, a chk-1 inhibitor for cancer. It has a clinical trial collaboration agreement with Merck to investigate the safety and efficacy of the companys MEK inhibitor, binimetinib, with Merck's anti-PD-1 therapy, KEYTRUDAÂ in metastatic colorectal cancer patients with microsatellite stable tumors; and a clinical research collaboration with Bristol-Myers Squibb to investigate the safety, tolerability and efficacy of Arrayâs investigational MEK inhibitor, binimetinib. Array BioPharma Inc. was founded in 1998 and is headquartered in Boulder, Colorado.
Array BioPharma Inc.’s ISS Governance QualityScore as of June 2, 2017 is 8. The pillar scores are Audit: 1; Board: 3; Shareholder Rights: 8; Compensation: 10.